X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs UNICHEM LAB - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS UNICHEM LAB IPCA LABS/
UNICHEM LAB
 
P/E (TTM) x 28.1 -64.1 - View Chart
P/BV x 3.3 0.7 464.1% View Chart
Dividend Yield % 0.1 2.4 6.0%  

Financials

 IPCA LABS   UNICHEM LAB
EQUITY SHARE DATA
    IPCA LABS
Mar-18
UNICHEM LAB
Mar-18
IPCA LABS/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs695382 182.0%   
Low Rs400234 170.9%   
Sales per share (Unadj.) Rs260.2116.3 223.7%  
Earnings per share (Unadj.) Rs19.0-18.9 -100.3%  
Cash flow per share (Unadj.) Rs33.1-11.7 -281.5%  
Dividends per share (Unadj.) Rs1.005.00 20.0%  
Dividend yield (eoy) %0.21.6 11.2%  
Book value per share (Unadj.) Rs213.0381.0 55.9%  
Shares outstanding (eoy) m126.2070.34 179.4%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.12.6 79.5%   
Avg P/E ratio x28.9-16.3 -177.3%  
P/CF ratio (eoy) x16.6-26.2 -63.1%  
Price / Book Value ratio x2.60.8 318.0%  
Dividend payout %5.3-26.4 -19.9%   
Avg Mkt Cap Rs m69,12021,668 319.0%   
No. of employees `00013.32.3 581.3%   
Total wages/salary Rs m7,3592,006 366.8%   
Avg. sales/employee Rs Th2,477.43,587.8 69.1%   
Avg. wages/employee Rs Th555.2880.0 63.1%   
Avg. net profit/employee Rs Th180.6-583.7 -30.9%   
INCOME DATA
Net Sales Rs m32,8368,180 401.4%  
Other income Rs m418610 68.5%   
Total revenues Rs m33,2548,790 378.3%   
Gross profit Rs m4,505-1,320 -341.2%  
Depreciation Rs m1,777505 351.9%   
Interest Rs m24080 299.9%   
Profit before tax Rs m2,905-1,295 -224.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m51133 1,529.3%   
Profit after tax Rs m2,394-1,331 -179.9%  
Gross profit margin %13.7-16.1 -85.0%  
Effective tax rate %17.6-2.6 -681.8%   
Net profit margin %7.3-16.3 -44.8%  
BALANCE SHEET DATA
Current assets Rs m19,45523,318 83.4%   
Current liabilities Rs m10,0764,635 217.4%   
Net working cap to sales %28.6228.4 12.5%  
Current ratio x1.95.0 38.4%  
Inventory Days Days98122 80.4%  
Debtors Days Days67121 55.1%  
Net fixed assets Rs m20,2608,163 248.2%   
Share capital Rs m252141 179.4%   
"Free" reserves Rs m26,63326,660 99.9%   
Net worth Rs m26,88626,801 100.3%   
Long term debt Rs m2,3403 70,912.1%   
Total assets Rs m41,17331,890 129.1%  
Interest coverage x13.1-15.2 -86.3%   
Debt to equity ratio x0.10 70,688.2%  
Sales to assets ratio x0.80.3 310.9%   
Return on assets %6.4-3.9 -163.1%  
Return on equity %8.9-5.0 -179.3%  
Return on capital %10.8-4.5 -237.0%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,6424,356 359.1%   
Fx outflow Rs m4,8840-   
Net fx Rs m10,7594,356 247.0%   
CASH FLOW
From Operations Rs m3,411-1,123 -303.7%  
From Investments Rs m-1,35416,487 -8.2%  
From Financial Activity Rs m-1,304-8,811 14.8%  
Net Cashflow Rs m7536,552 11.5%  

Share Holding

Indian Promoters % 45.9 50.1 91.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 15.1 75.5%  
FIIs % 25.3 3.0 843.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 31.7 54.9%  
Shareholders   36,892 20,176 182.9%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   ELDER PHARMA  FDC LTD.  ORCHID PHARMA LTD  DISHMAN PHARMA  TTK HEALTHCARE  

Compare IPCA LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 21, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - SUVEN LIFE COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS